Related Experiment Video

Updated: Jan 23, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Investigational drugs currently in phase II clinical trials for actinic keratosis

Flavia Lozzi1, Caterina Lanna1, Mauro Mazzeo1

  • 1a Department of Systems Medicine , University of Rome "Tor Vergata" , Rome , Italy.

Expert Opinion on Investigational Drugs
|June 25, 2019
PubMed
Abstract

Insights

Actinic keratoses (AKs) management requires field-directed therapies to prevent squamous cell carcinoma (SCC). Phase II trials explore novel agents targeting cell proliferation for effective AK treatment and cancer prevention.

Area of Science:

  • Dermatology
  • Oncology
  • Clinical Pharmacology

Background:

  • Actinic keratoses (AKs) are epidermal growths on sun-damaged skin, representing a field of cancerization.
  • Effective AK management necessitates field-directed therapies to prevent recurrence and squamous cell carcinoma (SCC).

Purpose of the Study:

  • To review Phase II clinical trials for actinic keratoses.
  • To analyze novel therapeutic agents, including proapoptotic drugs, immunomodulators, and chemopreventive agents.

Main Methods:

  • Focused on Phase II clinical trials for AKs using 'ClinicalTrials.Gov' as the primary reference.
  • Selected and discussed completed and ongoing trials, analyzing the chemical structure and mechanism of action of investigated molecules.

Main Results:

  • Identified various agents like VDA-1102, SR-T100, oleogel-S10, ICVT, eflornithine, isotretinoin, tretinoin, nicotinamide, perillyl alcohol, and liposomal T4N5.
  • Phase II trials indicate a therapeutic opportunity to selectively block cell proliferation regulators.

Conclusions:

  • AK therapy should be individualized based on patient profile, age, and AK site, considering local immune response.
  • Combining new molecules may offer synergistic effects to inhibit skin tumorigenesis.
  • Phase II trials reveal new strategies for targeting the field of cancerization and existing AKs.
Keywords:
Actinic keratosisinvestigational drugsphase II clinical trials

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Quantification of Filamentous Actin F-actin Puncta in Rat Cortical Neurons10:13

Quantification of Filamentous Actin F-actin Puncta in Rat Cortical Neurons

Published on: February 10, 2016

12.7K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.7K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K